Relapsed/Refractory B-Cell Lymphoma
Conditions
Brief summary
This is a phase 1 study of FT522 administered with rituximab in participants with relapsed/refractory B-cell lymphoma (R/R BCL). The primary objectives of the study are to evaluate the safety and tolerability of FT522 in combination with rituximab, and to determine the recommended phase 2 dose (RP2D) of FT522 in combination with rituximab; each objective will be assessed with or without conditioning chemotherapy.
Interventions
DRUGFT522
FT522 drug product is administered as an intravenous infusion on Days 1, 4 and 8 of a treatment cycle.
DRUGRituximab
Rituximab will be administered as an IV infusion on Day -4 of the treatment cycle.
DRUGCyclophosphamide
Cyclophosphamide will be administered as an IV infusion at a dose of 500 mg/m\^2 on Day -5, Day -4, and Day -3 of the treatment cycle.
DRUGFludarabine
Fludarabine will be administered as an IV infusion at a dose of 30 mg/m\^2 on Day -5, Day -4, and Day -3 of the treatment cycle.
DRUGBendamustine
Bendamustine will be administered as an IV infusion at a dose of 90 mg/m\^2 on Day -5 and Day -4 of the treatment cycle. Bendamustine may be administered as an alternative to cyclophosphamide/fludarabine.
Sponsors
Fate Therapeutics
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Masking description
The initial dose escalation stage of the study is nonrandomized; the dose optimization stage is randomized; the dose expansion stage is nonrandomized.
Intervention model description
Participants will be enrolled first into a dose-escalation stage, followed by a dose optimization stage, and a dose-expansion stage.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of B-cell lymphoma (BCL) as: (1) histologically documented lymphomas expected to express CD19 and CD20, including Grades 1 to 3B follicular lymphoma (FL), marginal zone lymphoma (MZL), Waldenstrom macroglobulinemia (WM), mantle cell lymphoma (MCL), transformed indolent non-Hodgkin lymphoma (tNHL), diffuse large B-cell lymphoma (DLBCL) \[not otherwise specified\], high-grade BCL, primary mediastinal BCL, and Richter transformation (RT; expansion part of study only); (2) R/R disease following at least 1 prior systemic regimen containing an anti-CD20 monoclonal antibody (mAb) for which the participant has no available curative treatment options; and (3) evaluable F-fluorodeoxyglucose (FDG)-avid disease, or measurable disease defined by at least one bi dimensionally measurable lesion * Male participants and female participants of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception
Exclusion criteria
* Females who are pregnant or breastfeeding * Eastern Cooperative Oncology Group (ECOG) Performance Status ≥2 * Body weight \<50 kg * Evidence of insufficient organ function * Receipt of any biological therapy, chemotherapy (except for rituximab), or any investigational therapy within 2 weeks prior to Day 1 or five half-lives, whichever is shorter; or localized radiation therapy to a target lesion within 14 days prior to Day 1 * Currently receiving or likely to require systemic immunosuppressive therapy, e.g., prednisone \>5 mg daily, for any reason from Day -5 to Day 29, with the exception of corticosteroids as a pre medication required for conditioning chemotherapy or rituximab * Prior allogeneic hematopoietic stem cell transplant (HSCT) or allogeneic chimeric antigen receptor (CAR) T-cell therapy within 6 months of Day 1, or ongoing requirement for systemic graft-versus-host disease (GvHD) therapy * Receipt of an allograft organ transplant * Non-malignant central nervous system (CNS) disease such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease or receipt of medications for these conditions in the 2-year period leading up to study enrollment * Clinically significant cardiovascular disease * Clinically significant infections * Receipt of a live vaccine \<6 weeks prior to start of study intervention * Known allergy to human albumin or DMSO * Any medical condition or clinical laboratory abnormality that per investigator or medical monitor judgement, precludes safe participation in and completion of the study, or that could affect compliance with protocol conduct or interpretation of results
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with dose limiting toxicities (DLTs) | From Day 1 through Day 29 of Cycle 1 | The number of participants experiencing ≥1 DLT will be reported. |
| Severity of DLTs | From Day 1 through Day 29 of Cycle 1 | The severity of DLTs will be determined according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, v5.0). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of Complete Response (DOCR) | Up to approximately 18 months | The DOCR is defined as the time from first CR to disease progression or death from any cause. |
| Progression-Free Survival (PFS) | Up to approximately 18 months | PFS is defined as the time from first study intervention to progressive disease or death from any cause. |
| Overall Response Rate (ORR) | Up to approximately 24 months | Participants will be classified into the following tumor response categories: complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), or not evaluable (NE) according to the Lugano 2014 criteria. The best overall response (BOR) will be summarized for the efficacy evaluable population. ORR is defined as the percentage of participants who achieve a PR or better during the study prior to any subsequent off-protocol anti-cancer therapy. |
| Area Under the Plasma-Concentration Time Curve (AUC) of FT522 | Cycle 1, Up to Day 29 | The plasma AUC of FT522 will be reported. |
| Maximum Plasma Concentration (Cmax) of FT522 | Cycle 1, Up to Day 29 | The plasma Cmax of FT522 will be reported. |
| Overall Survival (OS) | Up to approximately 18 months | OS is defined as the time from first dose of study intervention to death from any cause. |
| Duration of Response (DOR) | Up to approximately 18 months | The DOR is defined as the time from first objective response to disease progression or death from any cause. |
Countries
United States
Outcome results
None listed